Lamark Biotech Raises Rs 6.5 Crore for Innovative Solutions in Biopharma

Lamark Biotech, a promising biopharma startup, has successfully secured Rs 6.5 crore in a pre-Series A funding round spearheaded by the IAN Group. This investment also includes contributions from the IAN Alpha Fund, BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. The round saw participation from domain experts among IAN’s angel investors.

Based in Ahmedabad, Lamark Biotech had earlier obtained $41.3K in a seed funding round led by VIT-TBI and other investors.

The newly acquired funds will be directed towards accelerating the development of thermostable insulin and expanding the biologics platform, aimed at providing global accessibility, as stated by Lamark in their press release.

About Lamark Biotech’s Mission and Innovations

Founded in 2018 by Vaibhav Bhatia, Lamark Biotech seeks to transform drug delivery methods for chronic and life-altering diseases. Their innovative ProteoStrong platform facilitates the stabilization of delicate protein-based medicines, including insulin, monoclonal antibodies, and enzymes, while preserving their molecular integrity.

Research and Development Initiatives

Lamark Biotech utilizes the research and development capabilities of the Venture Center and NCL Innovation to advance a new range of temperature-resilient biologics. These products maintain their efficacy under extreme conditions, making them particularly suitable for regions lacking proper cold storage facilities.

Market Focus and Future Plans

With its leading product, InsulinStrong, Lamark aims to penetrate the Rs 4,000 crore Indian insulin market. The company has plans to expand its reach into Southeast Asia and the UAE. Over the next 24 months, Lamark Biotech intends to file for international patents, initiate early clinical trials, and establish collaborations with pharmaceutical companies, CDMOs, and global health organisations.